Improving In Vitro Antibody Production Using Synthetic Peptide Derived from RhD Loops.

Area of Science:

• Immunology
• Biotechnology
• Transfusion Medicine

Background:

• The RhD antigen is crucial for safe blood transfusions but poses risks like hemolytic transfusion reactions (HTRs).
• Conventional methods for generating anti-RhD antibodies face limitations including cost, availability, and ethical concerns.
• Developing an in vitro platform for antibody production is essential to overcome these challenges.

Purpose of the Study:

• To evaluate an in vitro immunization platform for producing anti-RhD antibodies.
• To compare the efficacy of full-length RhD protein versus a synthetic RhD peptide for antibody generation.
• To establish a rapid, ethical, and reproducible biotechnological alternative for antibody production.

Main Methods:

• Peripheral blood mononuclear cells (PBMCs) were isolated and stimulated with RhD protein, synthetic peptide, or peptide conjugated to Keyhole Limpet Hemocyanin (KLH).
• Cultures were supplemented with cytokines (IL-4, IFN-γ) and incubated for one week.
• Antibody production was quantified using ELISA.

Main Results:

• Conjugating the synthetic peptide to KLH significantly increased antibody levels compared to the free peptide.
• Both RhD protein and peptide-KLH stimulated antibody production, with combined stimulation yielding the highest levels.
• Two-step immunization and specific cytokine combinations (IL-4, IFN-γ) enhanced antibody responses.

Conclusions:

• Synthetic RhD peptide, particularly when conjugated to KLH, is a viable alternative to full-length protein for in vitro antibody production.
• This in vitro approach offers practical biotechnological applications for generating antibodies and antibody-producing clones.
• The platform reduces the reliance on traditional in vivo immunization methods.